CTNM Quote, Financials, Valuation and Earnings

CG Oncology, Inc. has a net margin of -- compared to Contineum Therapeutics, Inc.'s net margin of -2629.53%. Contineum Therapeutics, Inc.'s return on equity of -31.42% beat CG Oncology, Inc.'s return on equity of -22.73%.

Contineum Therapeutics, Inc. has a consensus price target of $22.04, signalling upside risk potential of 79.75%. On the other hand CG Oncology, Inc. has an analysts' consensus of $70.71 which suggests that it could grow by 76.43%. Given that Contineum Therapeutics, Inc. has higher upside potential than CG Oncology, Inc., analysts believe Contineum Therapeutics, Inc. is more attractive than CG Oncology, Inc..

Contineum Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CG Oncology, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Contineum Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CG Oncology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Contineum Therapeutics, Inc. pays -- of its earnings as a dividend. CG Oncology, Inc. pays out -- of its earnings as a dividend.

Contineum Therapeutics, Inc. quarterly revenues are --, which are smaller than CG Oncology, Inc. quarterly revenues of $1.7M. Contineum Therapeutics, Inc.'s net income of -$12.8M is higher than CG Oncology, Inc.'s net income of -$43.8M. Notably, Contineum Therapeutics, Inc.'s price-to-earnings ratio is 50.95x while CG Oncology, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Contineum Therapeutics, Inc. is -- versus 1,407.13x for CG Oncology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

CEL-SCI Corp. has a net margin of -- compared to Contineum Therapeutics, Inc.'s net margin of --. Contineum Therapeutics, Inc.'s return on equity of -31.42% beat CEL-SCI Corp.'s return on equity of -266.61%.

Contineum Therapeutics, Inc. has a consensus price target of $22.04, signalling upside risk potential of 79.75%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 836.12%. Given that CEL-SCI Corp. has higher upside potential than Contineum Therapeutics, Inc., analysts believe CEL-SCI Corp. is more attractive than Contineum Therapeutics, Inc..

Contineum Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Contineum Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Contineum Therapeutics, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Contineum Therapeutics, Inc. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. Contineum Therapeutics, Inc.'s net income of -$12.8M is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, Contineum Therapeutics, Inc.'s price-to-earnings ratio is 50.95x while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Contineum Therapeutics, Inc. is -- versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Denali Therapeutics, Inc. has a net margin of -- compared to Contineum Therapeutics, Inc.'s net margin of --. Contineum Therapeutics, Inc.'s return on equity of -31.42% beat Denali Therapeutics, Inc.'s return on equity of -44.34%.

Contineum Therapeutics, Inc. has a consensus price target of $22.04, signalling upside risk potential of 79.75%. On the other hand Denali Therapeutics, Inc. has an analysts' consensus of $32.21 which suggests that it could grow by 84.4%. Given that Denali Therapeutics, Inc. has higher upside potential than Contineum Therapeutics, Inc., analysts believe Denali Therapeutics, Inc. is more attractive than Contineum Therapeutics, Inc..

Contineum Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Denali Therapeutics, Inc. has a beta of 1.115, suggesting its more volatile than the S&P 500 by 11.475%.

Contineum Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Denali Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Contineum Therapeutics, Inc. pays -- of its earnings as a dividend. Denali Therapeutics, Inc. pays out -- of its earnings as a dividend.

Contineum Therapeutics, Inc. quarterly revenues are --, which are smaller than Denali Therapeutics, Inc. quarterly revenues of --. Contineum Therapeutics, Inc.'s net income of -$12.8M is higher than Denali Therapeutics, Inc.'s net income of -$126.9M. Notably, Contineum Therapeutics, Inc.'s price-to-earnings ratio is 50.95x while Denali Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Contineum Therapeutics, Inc. is -- versus 6.62x for Denali Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Recursion Pharmaceuticals, Inc. has a net margin of -- compared to Contineum Therapeutics, Inc.'s net margin of -3135.32%. Contineum Therapeutics, Inc.'s return on equity of -31.42% beat Recursion Pharmaceuticals, Inc.'s return on equity of -80.23%.

Contineum Therapeutics, Inc. has a consensus price target of $22.04, signalling upside risk potential of 79.75%. On the other hand Recursion Pharmaceuticals, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 59.09%. Given that Contineum Therapeutics, Inc. has higher upside potential than Recursion Pharmaceuticals, Inc., analysts believe Contineum Therapeutics, Inc. is more attractive than Recursion Pharmaceuticals, Inc..

Contineum Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Recursion Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Contineum Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Contineum Therapeutics, Inc. pays -- of its earnings as a dividend. Recursion Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Contineum Therapeutics, Inc. quarterly revenues are --, which are smaller than Recursion Pharmaceuticals, Inc. quarterly revenues of $5.2M. Contineum Therapeutics, Inc.'s net income of -$12.8M is higher than Recursion Pharmaceuticals, Inc.'s net income of -$162.3M. Notably, Contineum Therapeutics, Inc.'s price-to-earnings ratio is 50.95x while Recursion Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Contineum Therapeutics, Inc. is -- versus 40.36x for Recursion Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.